Reporting owner · CIK 0001760648

OrbiMed Capital GP VII LLC

SEC Form 4 history for the last 180 days across 3 companies, 56 transactions and 5 filings.

DIRElectra Therapeutics, Inc.
Open-market transaction mix100% buys22 buys · 0 sales

Period: Last 180 days

Trade dates in this period: Sep 21, 2026 – Nov 10, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings5Form 4 records
Buying$55.5M22 purchases
Selling$00 sales
Net value+$55.5MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
OrbiMed Capital GP VII LLC transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$16.9kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$175kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$132kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$33.0kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$311kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$77.1kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$915kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$226kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$141kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$35.4kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$289kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$72.1kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$777kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$192kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$767kView disclosure →
ETRAElectra Therapeutics, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$191kView disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a buy at Electra Therapeutics, Inc. on Nov 10, 2026 valued at $16,900.

Review SEC filing
Latest sale

No open-market insider sale is available.

Monthly open-market activity

Last 2 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Sep 202650$36,149,995$0+$36,149,995
Nov 2026170$19,349,646.99$0+$19,349,646.99

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$2.52M
Median P/S size$257k
Direct0
Indirect56
Nov 10, 2026buy

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

22 observations · Sep 21, 2026 – Nov 10, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 10, 20262,194,579 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Sep 21, 20262,002,310Sep 23, 2026View transaction
Sep 21, 20263,090,244Sep 23, 2026View transaction
Sep 21, 20264,793,558Sep 23, 2026View transaction
Sep 21, 20265,126,891Sep 23, 2026View transaction
Sep 21, 2026758,279Sep 23, 2026View transaction
Sep 21, 20261,758,279Sep 23, 2026View transaction
Nov 3, 20265,151,204Nov 5, 2026View transaction
Nov 3, 20261,856,079Nov 5, 2026View transaction
Nov 3, 20265,175,604Nov 5, 2026View transaction
Nov 3, 20261,954,679Nov 5, 2026View transaction
Nov 4, 20265,184,871Nov 5, 2026View transaction
Nov 4, 20261,991,779Nov 5, 2026View transaction
Nov 4, 20265,189,871Nov 5, 2026View transaction
Nov 4, 20262,011,779Nov 5, 2026View transaction
Nov 5, 20265,220,762Nov 5, 2026View transaction
Nov 5, 20262,136,979Nov 5, 2026View transaction
Nov 6, 20265,230,578Nov 10, 2026View transaction
Nov 6, 20262,176,579Nov 10, 2026View transaction
Nov 9, 20265,234,578Nov 10, 2026View transaction
Nov 9, 20262,192,579Nov 10, 2026View transaction
Nov 10, 20265,255,278Nov 10, 2026View transaction
Nov 10, 20262,194,579Nov 10, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

OrbiMed Capital GP VII LLC Insider Activity FAQ

SEC Form 4 context

Who is OrbiMed Capital GP VII LLC?

OrbiMed Capital GP VII LLC is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001760648.

Which companies has OrbiMed Capital GP VII LLC reported transactions for?

Electra Therapeutics, Inc., Aspen Neuroscience, Inc., ADARx Pharmaceuticals, Inc., MBX Biosciences, Inc., Passage BIO, Inc.

When was OrbiMed Capital GP VII LLC's latest insider buy?

The insider reported a buy at Electra Therapeutics, Inc. on Nov 10, 2026 valued at $16,900.

When was OrbiMed Capital GP VII LLC's latest insider sale?

No open-market insider sale is recorded in the last 180 days. Earlier filings are outside the visible history.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.